BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22012004)

  • 1. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.
    Kim DW; Kim SY; Kim HK; Kim SW; Shin SW; Kim JS; Park K; Lee MY; Heo DS
    Ann Oncol; 2007 Dec; 18(12):2009-14. PubMed ID: 17785767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
    Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
    Ahn HK; Jung M; Sym SJ; Shin DB; Kang SM; Kyung SY; Park JW; Jeong SH; Cho EK
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):277-82. PubMed ID: 24906423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
    Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.
    Park IH; Sohn JH; Kim SB; Lee KS; Chung JS; Lee SH; Kim TY; Jung KH; Cho EK; Kim YS; Song HS; Seo JH; Ryoo HM; Lee SA; Yoon SY; Kim CS; Kim YT; Kim SY; Jin MR; Ro J
    Cancer Res Treat; 2017 Jul; 49(3):569-577. PubMed ID: 27618821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
    Lee SW; Kim YM; Kim YT; Kang SB
    J Gynecol Oncol; 2017 May; 28(3):e26. PubMed ID: 28028994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).
    Lee SW; Kim YM; Cho CH; Kim YT; Kim SM; Hur SY; Kim JH; Kim BG; Kim SC; Ryu HS; Kang SB
    Cancer Res Treat; 2018 Jan; 50(1):195-203. PubMed ID: 28324920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
    Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
    Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer.
    Kim JY; Do YR; Song HS; Cho YY; Ryoo HM; Bae SH; Kim JG; Chae YS; Kang BW; Baek JH; Kim MK; Lee KH; Park K
    Anticancer Res; 2017 Mar; 37(3):1467-1473. PubMed ID: 28314319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.